Pelthos Therapeutics Inc. earnings releases PTHS

Annual Quarterly

Pelthos Therapeutics Inc. last reported quarterly results on Aug 13, 2026, for Q2 FY2026 (the quarter ended Jun 30, 2026): revenue of $15.6 million and diluted EPS of -$6.62. It usually reports 44–49 days after a quarter ends. Based on that pattern, the next release is estimated for around Nov 12, 2026.

Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 44–49 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.

Released Quarter Revenue Net income Diluted EPS
Aug 13, 2026
44 days after quarter end
Q2 FY2026
ended Jun 30, 2026
16
-23
-579.0%
-6.62
-25.1%
May 14, 2026
44 days after quarter end
Q1 FY2026
ended Mar 31, 2026
11
-25
-1174.0%
-7.57
-135.8%
Nov 13, 2025
44 days after quarter end
Q3 FY2025
ended Sep 30, 2025
0
-16
-858.0%
-5.30
Aug 18, 2025
49 days after quarter end
Q2 FY2025
ended Jun 30, 2025
—
-3
-94.6%
-5.29

Company profile

Industry
Biological Products, (No Diagnostic Substances) (SIC 2836)
Listed as
PTHS (NYSE)
Fiscal year ends
December 31
Incorporated in
NV
Headquarters
Durham, NC
SEC filer status
, Emerging growth company
SEC CIK
1919246
Former names
Channel Therapeutics Corp (until May 27, 2025); Chromocell Therapeutics Corp (until Nov 15, 2024)

Other Biological Products, (No Diagnostic Substances) companies

All 182 Biological Products, (No Diagnostic Substances) companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.